依达拉奉临床应用获益及其风险评价  

Benefits and risks of edaravone in clinical application

作　　者：王喆[1] 

机构地区：[1]解放军总医院第一附属医院药剂药理科,北京100048

出　　处：《中国临床药理学杂志》2015年第5期378-379,共2页The Chinese Journal of Clinical Pharmacology

摘　　要：依达拉奉是1种自由基清除剂,自2001年5月上市以来,用于急性脑梗死的治疗,随着临床应用范围的扩大,其严重的不良反应也逐渐显现出来。本文结合相关文献对依达拉奉临床应用的获益及其风险进行评价分析,以期在用药前结合患者基础疾病,达到合理用药的目的。Since listed in May 2001, edaravone, as a novel free radical scavenger, was widely used in the treatment of acute cerebral infarction. With the expansion of the clinical application scope, its serious adverse reactions were gradually revealed. In order to provide a reference for rational use of edaravone combined with the patients＇ basic disease before treatment, this article reviewed literature about benefits and risks of edaravone in clinical application and then evaluated.

关 键 词：依达拉奉 自由基清除剂 获益 风险 

分 类 号：R745.1[医药卫生—神经病学与精神病学]